

TABLE OF CONTENTS

July 13, 2009

No. 2147

BUSINESS

- 1 GSK Makes Full Entry into Oncology Market with Tykerb
- 2 Otsuka: Mainstay Products Drive Sales up to ¥440.4 Bil.
- 2 Bayer Moves Oncology Business Unit to Tokyo
- 3 Blopress Keeps Top Place 5 Years in a Row
- 6 FY2008 Sales of Ethical Drugs Up 2.9% to ¥8,368.6 Bil.: IMS Japan
 - Blopress Ranked No. 1, Diovan No. 2
- 6 **BUSINESS NEWS IN BRIEF**
 - Astellas Licenses Qutenza from NeurogesX in Europe
 - Takeda Completes Tender Offer for IDM Pharma
 - Toa Eiyo: Medet Tab. Drives Sales
 - DSP Creates Holding Company in US

REGULATORY

- 8 Alogliptin Approval to Be Delayed at Least 2 Years: Takeda
 - Fixed-Dose Combination of Alogliptin + Actos Applied for in Japan
 - Takeda May Even Abandon Development: Analyst
- 9 *Koroshō's* Council Recommends Early Development of Plerixafor
- 8 **REGULATORY NEWS IN BRIEF**
 - Rasilez, Avolve Recommended for Approval
 - Saxagliptin MAA Receives Positive Opinion in the EU
 - Total Review Period Increases in FY2008: PMDA

GENERICIS

- 10 Sandoz's Growth Hormone Approved as Japan's First Biosimilar
 - Sandoz's Somatropin Biosimilars to Be Priced at 70% of Original Product
- 10 JSGM Proposes Free Pricing System for Generics
- 11 *Koroshō* Asks MEXT to Cooperate to Increase Use of Generics by National Univ. Hospitals

SELF-MEDICATION

- 11 **NEW PRODUCTS**
 - J&J to Launch Cor-Tyzine for Nasal Allergy
- 17 JSMI Introduces New Voluntary GL for Ad of OTC Drugs

R&D

- 12 Kyowa Kirin Initiates PII Trial for KW-0761 in Japan
- 12 **R&D NEWS IN BRIEF**
 - Takeda Initiates PIII Trial for TAK-536 in Japan
 - BI, Vitae Ally for R&D of BACE Inhibitors for AD
 - PI, II Results on BAY 73-4506 Presented at ASCO: Bayer
 - Combination of Enbrel + MTX Inhibits Joint Damage in RA
 - Enbrel + MTX Combination Effective in Japanese RA Patients
 - Replagal Also Effective for Fabry Disease in Women: DSP
 - Tasigna Removes Cancer Cells from 96% of CML Patients: Novartis
 - Actemra Achieves 56% Remission Rate in Over 2 Years
 - Extended-Release BI-Sifrol as Effective as Immediate-Release Formulation
- 15 **NEW PRODUCTS**
 - NBI, Astellas: ARB + HCTZ Combination Tablet, Micombi
 - Eli Lilly Japan: Strattera for AD/HD
 - GSK: Tykerb Tablet for Breast Cancer
 - GSK: Allermist Nasal Spray for Allergic Rhinitis
 - Janssen: Risperdal Consta IM Injection

MEDICAL DEVICES

- 16 ExAblate 2000 Recommended for Approval for Treatment of Uterine Myoma
 - JIMRO's Blood Cell Remover Designated as Orphan Med Device
- 16 **MEDICAL DEVICE NEWS IN BRIEF**
 - ArBlast's Cultured Corneal Epithelial Cell Sheet Passes CDFS Committee
- 17 4 Med Materials Recommended for Health Insurance Coverage

MEDICAL FACILITIES & NURSING CARE

- 18 IP Injection of Paclitaxel Approved
- 18 New GL on COPD to Recommend b2 Stimulant + Inhaled Steroid Combinations
 - COPD Is a Systemic Disease
- 19 JSA Proposes Outline of Law on Measures against Stroke